Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [13558]

ASCO 2026: Cancer vaccine sustains 49 percent melanoma reduction after 5 years

ASCO 2026: Cancer vaccine sustains 49 percent melanoma reduction after 5 years

ASCO 2026: Mobile app for symptom monitoring could help people with advanced cancer maintain their quality of life

ASCO 2026: Mobile app for symptom monitoring could help people with advanced cancer maintain their quality of life

ASCO 2026: Galleri early detection test may shift timing of cancer detection, reducing stage IV diagnoses

ASCO 2026: Galleri early detection test may shift timing of cancer detection, reducing stage IV diagnoses

ASCO 2026: Some breast cancer patients with sentinel lymph node spread can safely skip axillary lymph node dissection

ASCO 2026: Some breast cancer patients with sentinel lymph node spread can safely skip axillary lymph node...

Targeted platinum-antibody conjugates boost tumour visibility to the immune system

Targeted platinum-antibody conjugates boost tumour visibility to the immune system

Blood test detects early signs of breast cancer recurrence

Blood test detects early signs of breast cancer recurrence

‘Intelligent tattoo' detects skin cancer before it appears

‘Intelligent tattoo' detects skin cancer before it appears

Positive EU CHMP opinion for pembrolizumab in combination with enfortumab vedotin-ejfv as perioperative treatment in muscle-invasive bladder cancer

Positive EU CHMP opinion for pembrolizumab in combination with enfortumab vedotin-ejfv as perioperative treatment...

ASCO 2026: Personalised vaccine boosts immune activity against brain cancer

ASCO 2026: Personalised vaccine boosts immune activity against brain cancer

ASCO 2026: Phase 3 PEAK study could usher in new second-line therapy for GIST

ASCO 2026: Phase 3 PEAK study could usher in new second-line therapy for GIST

More from ecancer